Nordic Pharma’s Lacrifill Canalicular Gel Highlighted in DEWS III Report
Nordic Pharma, a subsidiary of Nordic Group BV, announced that its Lacrifill Canalicular Gel—a novel therapy for the relief of dry eye symptoms—has been featured in the newly released Dry Eye Workshop (DEWS) III report from the Tear Film and Ocular Surface Society (TFOS).
The TFOS DEWS III report, published in the June 2025 issue of the American Journal of Ophthalmology, cites two clinical studies evaluating Nordic Pharma’s crosslinked hyaluronic acid (HA) canalicular filler in Section 6.2.4, “Newer Plug Designs and Other Technologies.”
First study: Demonstrates improvements in corneal staining, Schirmer test scores, and other key measures three months post-treatment
Second study: Compares Lacrifill Canalicular Gel to a commercially available hydrogel canalicular plug, finding it safe, well-tolerated, and delivering statistically significant symptom and sign improvements sustained over 6 months
Lacrifill research will also be in the spotlight at the Women in Ophthalmology (WIO) Summer Symposium, August 7–10.
Monica Patel, MD—founder and Medical Director of Clear Vision Ophthalmology—will present a poster titled:
“Evaluation of Lacrimal Punctal Plug Insertion for Dry Eye Relief in Ophthalmology Clinic Patients Using Self-Reported Improvement and OSDI Questionnaires.”
In this study of 117 patients 1 month after LACRIFILL placement:
66.25% reported at least 50% symptom improvement
The majority in this group reported 90 to 100% improvement, particularly in burning and “sandiness” sensations
Benefits were observed across all patient groups, including those with comorbidities such as diabetes, thyroid disease, and glaucoma
Dr. Patel emphasized the value of correlating subjective patient reports with OSDI scores, noting that self-reporting can be a valid and efficient tool for assessing new therapies.
Chief Commercial Officer of Eye Care U.S., Jai Parekh, MD, MBA, praised the results, calling the data “a well-done, real-time study” demonstrating consistent efficacy in symptom relief.
Two recent case studies further support Lacrifill's effectiveness:
Post–Refractive Cataract Surgery (Jennifer Loh, MD, CRST, June 2025): In a patient with post-surgical blurriness unresponsive to conventional treatments, LACRIFILL improved both uncorrected visual acuity and visual quality by stabilizing the tear film.
DED with Demodex Blepharitis (Selina McGee, OD, FAAO, Modern Optometry, May/June 2025): Treatment resulted in significant SPEED score improvement, resolution of inferior corneal staining, and increased tear meniscus height.